B. Metzler seel. Sohn & Co. AG Boosts Stock Position in Gilead Sciences, Inc. $GILD

B. Metzler seel. Sohn & Co. AG raised its position in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 11.3% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 114,360 shares of the biopharmaceutical company's stock after purchasing an additional 11,592 shares during the period. B. Metzler seel. Sohn & Co. AG's holdings in Gilead Sciences were worth $14,448,000 at the end of the most recent reporting period.

Several other hedge funds also recently modified their holdings of GILD. Natural Investments LLC grew its holdings in shares of Gilead Sciences by 4.0% during the second quarter. Natural Investments LLC now owns 7,354 shares of the biopharmaceutical company's stock worth $929,000 after buying an additional 282 shares in the last quarter. Symphony Financial Ltd. Co. raised its position in shares of Gilead Sciences by 39.8% in the second quarter. Symphony Financial Ltd. Co. now owns 3,533 shares of the biopharmaceutical company's stock valued at $446,000 after buying an additional 1,005 shares during the last quarter. Acorn Wealth Advisors LLC lifted its stake in shares of Gilead Sciences by 14.5% during the second quarter. Acorn Wealth Advisors LLC now owns 2,630 shares of the biopharmaceutical company's stock valued at $332,000 after buying an additional 333 shares during the period. Triumph Capital Management boosted its position in Gilead Sciences by 2.2% during the second quarter. Triumph Capital Management now owns 3,687 shares of the biopharmaceutical company's stock worth $466,000 after acquiring an additional 80 shares during the last quarter. Finally, Proficio Capital Partners LLC acquired a new stake in Gilead Sciences during the second quarter worth approximately $557,000. 83.67% of the stock is owned by institutional investors and hedge funds.

Gilead Sciences News Roundup

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Zacks upgraded Gilead to “Strong Buy.” The upgrade reflects improving expectations for the company’s earnings outlook and could encourage additional buying interest. Gilead Upgraded to Strong Buy
• Positive Sentiment: Zacks raised its 2027 EPS forecasts across every quarter and for the full year. Estimates increased to $2.09 for Q1, $2.24 for Q2, $2.43 for Q3, $2.60 for Q4 and $9.36 for full-year 2027, signaling modestly stronger anticipated profitability. Zacks Gilead Upgrade and Forecasts
• Positive Sentiment: FDA approval of Bixlenvo expands Gilead’s HIV portfolio. The single-tablet treatment is aimed at underserved patients and could provide a new source of growth, though commercial adoption will determine its financial impact. Bixlenvo HIV Growth Opportunity
• Neutral Sentiment: CEO Daniel O’Day sold 15,000 shares worth approximately $2.23 million. The transaction reduced his holdings by 2.53%, but it was executed under a pre-arranged Rule 10b5-1 plan, making it a weaker bearish signal than an unexpected discretionary sale. SEC Insider Trading Filing

Insiders Place Their Bets

In related news, insider Johanna Mercier sold 28,000 shares of the firm's stock in a transaction that occurred on Monday, August 17th. The shares were sold at an average price of $137.64, for a total value of $3,853,920.00. Following the transaction, the insider owned 118,234 shares in the company, valued at approximately $16,273,727.76. This trade represents a 19.15% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Andrew D. Dickinson sold 3,000 shares of Gilead Sciences stock in a transaction that occurred on Monday, August 17th. The shares were sold at an average price of $138.36, for a total transaction of $415,080.00. Following the transaction, the chief financial officer directly owned 165,646 shares in the company, valued at approximately $22,918,780.56. This trade represents a 1.78% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 105,000 shares of company stock worth $14,495,820. 0.30% of the stock is owned by insiders.

Gilead Sciences Trading Down 0.2%

GILD stock opened at $149.61 on Thursday. The company has a quick ratio of 1.09, a current ratio of 1.27 and a debt-to-equity ratio of 2.03. The company has a market cap of $185.51 billion, a price-to-earnings ratio of -56.03 and a beta of 0.33. The business has a fifty day simple moving average of $135.66 and a 200-day simple moving average of $136.45. Gilead Sciences, Inc. has a 52 week low of $108.46 and a 52 week high of $157.29.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last issued its earnings results on Monday, August 3rd. The biopharmaceutical company reported ($6.75) earnings per share for the quarter, beating analysts' consensus estimates of ($7.25) by $0.50. Gilead Sciences had a negative return on equity of 2.11% and a negative net margin of 10.64%.The firm had revenue of $7.80 billion for the quarter, compared to analysts' expectations of $7.40 billion. During the same quarter last year, the firm earned $2.01 earnings per share. The firm's revenue for the quarter was up 10.6% compared to the same quarter last year. On average, equities research analysts expect that Gilead Sciences, Inc. will post -0.47 EPS for the current year.

Gilead Sciences Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 29th. Stockholders of record on Tuesday, September 15th will be issued a $0.82 dividend. This represents a $3.28 dividend on an annualized basis and a dividend yield of 2.2%. The ex-dividend date is Tuesday, September 15th. Gilead Sciences's dividend payout ratio (DPR) is -122.85%.

Analysts Set New Price Targets

Several research analysts have weighed in on GILD shares. Daiwa Securities Group cut their price target on Gilead Sciences from $161.00 to $150.00 and set an "outperform" rating for the company in a report on Tuesday, May 19th. Zacks Research upgraded Gilead Sciences from a "hold" rating to a "strong-buy" rating in a report on Monday. Morgan Stanley lowered their price objective on Gilead Sciences from $166.00 to $165.00 and set an "overweight" rating for the company in a research report on Monday, July 27th. HSBC upgraded Gilead Sciences from a "hold" rating to a "buy" rating and increased their target price for the stock from $133.00 to $155.00 in a research report on Monday, July 6th. Finally, Royal Bank Of Canada lifted their price target on Gilead Sciences from $120.00 to $123.00 and gave the company a "sector perform" rating in a report on Wednesday, August 5th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-four have assigned a Buy rating and five have given a Hold rating to the company. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $158.04.

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead's product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source